Shares of Tempus AI (NASDAQ: TEM) surged 5.12% in pre-market trading on Tuesday, as the precision medicine technology company announced a significant milestone for its comprehensive liquid biopsy assay, xF+. The rally was fueled by the publication of a validation study in the prestigious Journal of Molecular Diagnostics, which adds substantial credibility to Tempus AI's product offering.

The study, titled "Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy," supports the utility of xF+ as a non-invasive technique for detecting actionable variants, identifying clinically relevant biomarkers, and monitoring disease progression. The xF+ panel, introduced in 2022, covers 523 genes spanning approximately 1.8 Mb of the human genome and has demonstrated high accuracy, sensitivity, and specificity in clinical samples and reference standards.

Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus, commented on the publication, stating, "When we first introduced xF+ in 2022, it was one of the largest clinically available liquid biopsy panels offered to physicians. We have since continued to refine the assay, and are thrilled to further demonstrate its analytical validity in a peer-reviewed study." The positive market reaction suggests that investors are optimistic about the potential impact of this validation on Tempus AI's future growth and market position in the precision medicine space, particularly in its ability to attract more physicians and partners to adopt its AI-driven technology platform.